Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/41555| metadata.artigo.dc.title: | Use of anakinra in severe COVID-19: a case report |
| metadata.artigo.dc.creator: | Filocamo, Giovanni Mangioni, Davide Tagliabue, Paola Aliberti, Stefano Costantino, Giorgio Minoia, Francesca Bandera, Alessandra |
| metadata.artigo.dc.subject: | Anakinra COVID-19 - Treatment |
| metadata.artigo.dc.publisher: | Elsevier |
| metadata.artigo.dc.date.issued: | Jul-2020 |
| metadata.artigo.dc.identifier.citation: | FILOCAMO, G. et al. Use of anakinra in severe COVID-19: a case report. International Journal of Infectious Diseases, [S.l.], v. 96, p. 607-609, July 2020. |
| metadata.artigo.dc.description.abstract: | Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra). |
| metadata.artigo.dc.identifier.uri: | https://www.sciencedirect.com/science/article/pii/S1201971220303337 http://repositorio.ufla.br/jspui/handle/1/41555 |
| metadata.artigo.dc.language: | en_US |
| Appears in Collections: | FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19) |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.